

 **SERVImed**
 **iROMED Group**

ribohyal

HYPOSMOLAR GEL
FOR DRY EYE SYNDROME


0 Y 0
CARO



HYPOSMOLAR GEL FOR DRY EYE SYNDROME

Hyposmolar gel for dry eye syndrome based on **Ribohyal® (HAr)**, the new chemical entity developed by SERVImed & Iromed. It is indicated for Dry Eye (mild to severe), patients with symptoms like photophobia, and need for long lasting lubrication due to its ability to stay on the ocular surface. The **Ribohyal®** NCE, compared to standard HA, has a higher resistance to the hyaluronase enzymatic degradation. Preservative and emulsifier free.

ADVANTAGES OF THE NEW CHEMICAL ENTITY **ribohyal®**



The NCE **Ribohyal® (HAr)** is synthesized by covalently binding riboflavin to hyaluronic acid's COOH and OH groups. Having less OH groups in the NCE makes it resistant to a fast hyaluronidase enzymatic degradation. This providing several advantages over standard and cross-linked hyaluronic acids:

- Has similar mechanical properties to unmodified HA
- Better supports enzymatic degradation, due to the reduction of the COOH and OH groups
- Is more stable than cross-linked hyaluronic acids
- Has a longer permanence time on the ocular surface

IN PRESS PUBLICATION

- 15 patients: 10 followed for Dry Eye, 5 for post-surgical corneal lesions
- Measurements : OSDI and BUT + Schirmer test
- Ribohyal showed greater lubricating and regenerative abilities, in less time, than the application of HA-based eye drops alone at the same concentration (control)
- Index improvement measured with the TearCheck® device

1) C. Caruso, R. Piscopo, M. Rinaldi, I. Senese, L. D'Andrea, C. Costagliola. "A New Chemical Entity as lubricant eye drops in the treatment on Dry Eye: a prospective, comparative double blind randomized study". In Press.

LUBRICATES AND PROTECTS

Lubricates the cornea and conjunctiva with a nourishing, protective and antioxidant action against external environmental insults.

REBALANCES TEAR OSMOLARITY

Its hypotonicity allows to restore the balance of the hyperosmolar tear present in dry eye syndrome.

RENEWS THE LIPID PHASE OF THE TEAR FILM

At each instillation, it creates a protective "jacket" that replenishes and renews the lipid phase of the tear film, preventing premature evaporation and destabilization of the tear as occurs in the dysfunction of the Meibomian gland. Vitamin E TPGS creates amphiphilic micellar structures, allowing Ribohyal to promote the natural restoration of the altered lipid layer. In addition, it promotes the anchoring of hyaluronic acid to the ocular surface receptors, contributing to the natural restoration of the mucous layer of the tear film.



NEW CHEMICAL ENTITY

Patented formulation with **Ribohyal**[®] & Vitamin E TPGS

Colored and transparent

Protective effect

Higher stability thanks to the NCE **Ribohyal**[®]

Longer permanence on the eye (3-4 hours)

HYPOSMOLAR

Restores the hyperosmolar tear balance in dry eye syndrome

Improved distribution and persistence on the ocular surface

Improved indexes of the altered tear film in Dry Eye

Photophobia reduction (1)

EASY AND COMFORTABLE APPLICATION

Applied like regular eye drops

Fast distribution on the ocular surface

Creates a protective layer that stabilizes the tear film

Counteracts the premature evaporation of the tear

The solution is well tolerated, maintains the same refractive index as the tear and does not alter vision



PATENTS: Italy, Europe.



SERVimed Industrial S.p.A.

Via Tempio del Cielo 3/5, 00144 Rome (Italy)
Tel: +39 06 92595490 Fax: +39 06 89360010
Email: info@servimedindustrial.com
www.servimed-industrial.com



Iromed Group S.r.l.

Via Tempio del Cielo 3/5, 00144 Rome (Italy)
Email: info@iromedgroup.com
www.iromedgroup.com

